RT Journal Article
SR Electronic
T1 Transmission potential of mpox in Mainland China, June-July 2023: estimating reproduction number during the initial phase of the epidemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.23.23296017
DO 10.1101/2023.09.23.23296017
A1 Akhmetzhanov, Andrei R.
A1 Wu, Pei-Hsuan
YR 2023
UL http://medrxiv.org/content/early/2023/10/05/2023.09.23.23296017.abstract
AB Despite reporting very few mpox cases in early 2023, Mainland China observed a surge of over 500 cases during the summer. Amid ambiguous prevention strategies and stigma surrounding mpox transmission, the epidemic silently escalated. This study aims to quantify the scale of the mpox epidemic and assess the transmission dynamics of the virus by estimating the effective reproduction number (Re) during its early phase. Publicly available data were aggregated to obtain daily mpox incidences in Mainland China, and the Re was estimated using an exponential growth model. The mean Re value was found to be 1.76 (95% credible interval: 1.51–2.06), suggesting a case doubling time of approximately 2 weeks. This estimate was compared with Re values from 16 other countries’ national outbreaks in 2022 that had cumulative incidences exceeding 700 symptomatic cases by the end of that year. The Re estimates for these outbreaks ranged from 1.17 for Portugal to 2.88 for Colombia. The pooled mean Re was 1.66 (95% credible interval: 1.40–1.92), which aligns closely with the Re for Mainland China. These findings underscore the need for immediate and effective control measures including targeted vaccination campaigns to mitigate the further spread and impact of the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Science and Technology Council, Taiwan (NSTC #111-2314-B-002-289).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at the github https://github.com/aakhmetz/Mpox-in-MainlandChina-2023 All data used for this study can be found at: https://github.com/aakhmetz/Mpox-in-MainlandChina-2023/tree/main/data